openPR Logo
Press release

Interleukin-6 (IL-6) Inhibitors Pipeline to Witness Growth due to Positive Clinical Results in the Coming Years | Top Key Players are Roche, Regeneron Pharmaceuticals, Inc., Sanofi, Janssen Inc., NovImmune, UCB

05-22-2019 08:43 AM CET | Health & Medicine

Press release from: Interleukin-6 (IL-6) Inhibitors -Pharma Proff

Interleukin-6 (IL-6) Inhibitors Pipeline to Witness Growth due

IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6α receptor. This protein is assumed to be actively involved in pyrogenesis, cancer, rheumatoid arthritis, diabetes mellitus, and schizophrenia. The IL-6 inhibitors target the IL-6 receptors, thereby blocking the signaling pathway between receptors and mediators of inflammation that stimulate the accumulation of B cells.

Download the sample report at: https://www.pharmaproff.com/request-sample/1222

Some of the approved medications acting as antagonists of IL-6 include Actmera (F. Hoffmann-La Roche Ltd.), Kevzara (Regeneron Pharmaceuticals Inc. and Sanofi-aventis Groupe), and Sylvant (Janssen Global Services LLC).

According to the research, drugs being developed as IL-6 inhibitors, most of which are in clinical phases and can be expected to be given orally. It has been observed that the oral route of medications is convenient, available in delayed or rapid release formulation, less risk of systemic infections, and inexpensive in nature, and also provides improved patient’s compliance.

Get the detailed analysis at: https://www.pharmaproff.com/report/interleukin-6-inhibitors-therapeutics-pipeline

Companies that are involved in developing anti-IL-6 therapeutics have shown positive clinical results in the various phases of drug development. For instance, in May 2015, Regeneron Pharmaceuticals Inc. and Sanofi-aventis Groupe announced positive data of phase III trial of sarilumab (Kevzara) for the treatment of patients with rheumatoid arthritis. The results of the study concluded that treatment with sarilumab has a favorable safety and tolerability profile, leading to the improvement of signs and symptoms of rheumatoid arthritis as compared to placebo.

Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1222

Designations Granted by Regulatory Authorities will Help the IL-6 Inhibitors Market to Grow
In June 2015, the U.S. Food and Drug Administration (USFDA) granted Breakthrough Therapy Designation to F. Hoffmann-La Roche Ltd.’s Actmera for the treatment of systemic sclerosis. Thus, such designation paces up the development process of the drug and helps it to reach the market sooner. Therefore, the designations will help the market to grow significantly.

Some of the companies involved in the development of IL-6 inhibitors include F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., Sanofi-aventis Groupe, Janssen Global Services LLC, Novimmune SA, UCB Pharma.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Interleukin-6 (IL-6) Inhibitors Pipeline to Witness Growth due to Positive Clinical Results in the Coming Years | Top Key Players are Roche, Regeneron Pharmaceuticals, Inc., Sanofi, Janssen Inc., NovImmune, UCB here

News-ID: 1748492 • Views:

More Releases for Pharma

Antiemetics Market Size 2022 Analysis by Top Key Players| Acacia Pharma Group Pl …
Antiemetics Market research added by the Absolute Markets Insights, offers a comprehensive analysis of growth trends prevailing in the global business domain. This report also provides definitive data concerning market, size, commercialization aspects and revenue forecast of the industry. In addition, the study explicitly highlights the competitive status of key players within the projection timeline while focusing on their portfolio and regional expansion endeavors. Access the PDF sample of the report@
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis. Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382 The Indomethacin Global Market Research Report provides close monitoring
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024. Global Roxatidine Market overview: Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the
Indometacin Market Top Key Manufacturers Aidarex, Ratiopharm, Merck, Xinhua Phar …
The Global Indometacin Market is a nonsteroidal anti-inflammatory drug commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. The demand for nonsteroidal anti-inflammatory drug has been increasing owing to the emergence of anti-inflammatory biologics that are more targeted. However, such as side effects of anti-inflammatory drugs and patent expiry issues may hamper the market growth in the review period. For More Info, Get Sample Report
Hydroxycarbamide Market Study Report 2019| Taj Pharma, Beijing Jialin Pharma, Qi …
Los Angeles, United State, June 11, 2019, - The global Hydroxycarbamide market is expected to surge at a steady CAGR in the coming years, states the latest QY Research report. The publication offers an insightful take on the historical data of the market and the milestones it has achieved. The report also includes an assessment of current market trends and dynamics, which helps in mapping the trajectory of the global Hydroxycarbamide
TIGLUTIK Market 2019: Top Players are Sanofi, Mylan Pharma, Apotex, Glemark Gene …
TIGLUTIK Market 2019 Report analyses the industry status, size, share, trends, growth opportunity, competition landscape and forecast to 2025. This report also provides data on patterns, improvements, target business sectors, limits and advancements. Furthermore, this research report categorizes the market by companies, region, type and end-use industry. Get Sample Copy of this Report@ https://www.researchreportsworld.com/enquiry/request-sample/13709986 Global TIGLUTIK market 2019 research provides a basic overview of the industry including definitions, classifications, applications